Selected article for: "death risk and hospitalization require"

Author: Roy, Somnath; Ghosh, Joydeep; Ganguly, Sandip; Mondal, Debapriya; Dabkara, Deepak; Chatterji, Soumyadip; Biswas, Bivas
Title: Outcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern India
  • Cord-id: zlpu8xh3
  • Document date: 2021_9_10
  • ID: zlpu8xh3
    Snippet: PURPOSE: The COVID-19 pandemic has imposed a unique challenge to oncology patients. Outcome data on COVID-19 in patients with cancer from the Indian subcontinent are scarce in the literature. We aimed to evaluate the outcome of patients with COVID-19 on active systemic anticancer therapy. MATERIALS AND METHODS: This is a retrospective study of patients with solid organ malignancies undergoing systemic therapy with a diagnosis of COVID-19 between March 2020 and February 2021. COVID-19 was diagnos
    Document: PURPOSE: The COVID-19 pandemic has imposed a unique challenge to oncology patients. Outcome data on COVID-19 in patients with cancer from the Indian subcontinent are scarce in the literature. We aimed to evaluate the outcome of patients with COVID-19 on active systemic anticancer therapy. MATERIALS AND METHODS: This is a retrospective study of patients with solid organ malignancies undergoing systemic therapy with a diagnosis of COVID-19 between March 2020 and February 2021. COVID-19 was diagnosed if a reverse transcriptase polymerase chain reaction assay from oropharyngeal or nasopharyngeal swab was positive for severe acute respiratory syndrome coronavirus 2. The objectives were to evaluate the outcome of COVID-19 and factors predicting the outcome. RESULTS: A total of 145 patients were included with a median age of 58 years (range, 20-81 years). Treatment was curative in 60 (42%) patients. Of all symptomatic cases (n = 88, 61%), 50 had mild, 27 had moderate and 19 had severe COVID-19–related symptoms as per WHO criteria. Fifty (34%) patients required hospitalization with a median duration of hospital stay of 12 days (range, 4-25 days); five patients required intensive care unit admission. The rest were treated with home isolation and did not require further hospitalization. Twenty-two (15%) patients died, and the risk of death was significantly associated with severity of symptoms (odds ratio, 91.3; 95% CI, 9.1 to 919.5, P = .0001) but not with any other clinical factors. Drug holiday was given to 63 (44%) patients with a median duration of 25 days (range, 7-88 days). The median duration to reverse transcriptase polymerase chain reaction–negative was 16 days (range, 7-62 days). CONCLUSION: COVD-19–related death rate was 15% among patients with solid organ malignancies. The severity of the symptoms was related to mortality. The majority of patients with mild symptoms were treated at home isolation.

    Search related documents:
    Co phrase search for related documents
    • active systemic therapy and logistic regression analysis: 1, 2
    • active systemic therapy and lung cancer: 1
    • active systemic treatment and logistic regression analysis: 1
    • admission require and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8
    • admission require and lymphocyte neutrophil: 1, 2, 3, 4
    • logistic regression analysis and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • logistic regression analysis and lung cancer patient: 1
    • logistic regression analysis and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lung cancer and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6, 7, 8
    Co phrase search for related documents, hyperlinks ordered by date